Zhejiang Ausun Pharmaceutical (603229.SH): Imatinib Mesylate tablets obtain drug registration certificate.

Zhejiang Ausun Pharmaceutical (603229.SH) announced that its wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd. (referred to as "Qizheng Pharmaceutical") has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the Imatinib Mesylate Tablets. The announcement indicates that Imatinib Mesylate Tablets is the world's first targeted anti-tumor molecular drug, used for the treatment of chronic myeloid leukemia (CML) in the accelerated or blast phase, patients in chronic phase who have failed interferon therapy, as well as patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). Its active ingredient, imatinib, is a tyrosine kinase inhibitor that effectively suppresses the Philadelphia chromosome gene, inhibiting abnormal white blood cell proliferation by preventing catalysis of phosphorylation reactions and loss of chromosome function. It can also bind to the active site of tyrosine kinases and inhibit their activity.